Drug intelligence / Profile preview

ALY-302

Development stage: Preclinical
Lead developer: Alys Pharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules

Overview

ALY-302 is an antibody-drug conjugate (ADC) developed by Alys Pharmaceuticals for the treatment of systemic mastocytosis and potentially other neoplastic, immune system, and skin/musculoskeletal diseases. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic agent designed to selectively target and kill diseased cells while sparing healthy tissue. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval. Its precise molecular target(s) and mechanism(s) of action have not been publicly disclosed as of June 2025[1][2].

Beyond the preview

Go deeper on ALY-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALY-302.

Explore the full profile